Loading market dashboard
Gilead Sciences, Inc.
GILDHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Assembly Biosciences NASDAQ: ASMB is awaiting a key development plan from partner Gilead Sciences for its herpes simplex virus programs while advancing ABI-6250 into multiple liver disease indications, Chief Executive Officer Jason Okazaki said during a Jefferies biotech event.
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Access--Gilead applauds the leadership of the Government of South Africa and the Global Fund for accelerating access to lenacapavir, a long-acting HIV prevention medication. This marks an important step toward expanding access to lenacapavir for communities most affected by HIV. “South Africa is at the heart of global efforts to end HIV. With the country's launch of lenacapavir, there is now an opportunity to rapidly accelerate progress,” said Daniel O'Day, Chairma.
Companies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases
FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) and Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT) today announced the successful completion of the previously announced acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases. The acquisition adds gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager, to Gilead's growing inflammation portfolio and will be the foundation of Lakefront's clinical de.
Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.
Compare diversification strategies and see how each ETF's unique index focus shapes risk and return for healthcare sector investors.
Gilead reports positive phase III IDEAL results as Livdelzi boosts ALP normalization in PBC patients, supporting regulatory discussions.
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Gilead Sciences, Inc. (NASDAQ) on Tuesday released results from the Phase 3 IDEAL study in people with primary biliary cholangitis (PBC).
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from a Phase 3 study in people with primary biliary cholangitis (PBC), showing that treatment with Livdelzi® (seladelpar) led to significantly more patients achieving normalization of alkaline phosphatase (ALP), a key liver marker of disease progression, compared with placebo after 52 weeks. The primary endpoint was defined as a composite of ALP ≤ 1.0× upper limit of normal (ULN) and a ≥.
Gilead Sciences, Inc. (GILD) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Gilead Sciences, Inc. (Nasdaq: GILD) today shared new results from a post hoc analysis showing that Livdelzi (seladelpar) was associated with high and sustai
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today shared new results from a post hoc analysis showing that Livdelzi® (seladelpar) was associated with high and sustained rates of normalization of a key liver marker (ALP) in people living with primary biliary cholangitis (PBC). In an ongoing Phase 3 study, participants with elevated ALP levels (between 1.0 and 1.67×ULN) experienced reductions in ALP after treatment. These data highlight the potential role of Livdelz.
Gilead wins FDA approval for Hepcludex, the first U.S. therapy for chronic HDV, while Trodelvy advances in Europe for TNBC.
Gilead Sciences NASDAQ: GILD Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC Capital Markets senior biotech analyst Brian Abrahams.
The U.S. Food and Drug Administration said on Friday it approved Gilead Sciences' drug for a rare and deadly liver infection that previously had no approved treatment options.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Hepcludex® (bulevirtide-gmod) 8.5 mg for the treatment of adults living with chronic hepatitis delta virus (HDV) infection, making it the first and only approved treatment for HDV in the United States. The FDA granted accelerated approval to Hepcludex based on reductions in HDV RNA and normalization of alanine aminotrans.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Hepcludex (bulevir
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorization of Trodelvy® (sacituzumab govitecan-hziy) as a monotherapy for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for met.
FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that together with Kite, a Gilead company, it will present more than 25 abstracts, including six oral presentations, at the 2026 ASCO Annual Meeting (May 29 – June 2) and the 2026 EHA Congress (June 11 – 14). These presentations underscore the increasing diversity of Gilead's oncology portfolio and pipeline reflecting a growing body of evidence across both solid tumors and hematolog.
Gilead Sciences, Inc. once again demonstrated strong performance of Trodelvy, Livdelzi, and Yeztugo. This "trio" generated $701 million in revenue for Gilead in Q1, up 110.5% quarter-on-quarter. However, Gilead's cell therapy franchise is once again struggling, with sales of Yescarta and Tecartus falling 12.3% YoY.
Moderna (NASDAQ:MRNA | MRNA Price Prediction) is back in the headlines after ripping 63.17% higher year to date on a surprise Q1 revenue triple and renewed pipeline excitement.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs). The acquisition brings Gilead next-generation ADC assets and a platform designed to maximize patient benefit through more selective delivery of diverse payloads to tumors. Tubulis' technologies enable th.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced a renewed five-year collaboration with the World Health Organization (WHO), committing funding, strategic
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a renewed five-year collaboration with the World Health Organization (WHO), committing funding, strategic support and product donations to accelerate progress toward eliminating visceral leishmaniasis (VL), also known as kala-azar. VL, the second deadliest parasitic disease after malaria, is a sandfly-borne illness that attacks internal organs and can be fatal if untreated. The expanded agreement aims to.
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Gilead Sciences, Inc. (GILD) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Gilead Sciences NASDAQ: GILD Chief Commercial Officer and Head of Corporate Affairs Johanna Mercier said the company is leaning on its HIV business while continuing to build out oncology and inflammation through recent acquisitions and pipeline development.
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $3 billion, in an underwritten, registered public offering, consisting of $500 million of 4.250% senior notes maturing in 2028, $1 billion of 4.400% senior notes maturing in 2029, $1 billion of 4.600% senior notes maturi.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Gilead Sciences is executing a successful transition from a mature antiviral company to a diversified therapeutic platform, driving a 34% stock rally. HIV revenue grew 10% YoY, with Yeztugo's explosive PrEP growth and raised guidance to $1B, signaling a durable, long-acting franchise. Oncology is gaining strategic coherence, led by Trodelvy's 37% YoY growth and platform expansion via acquisitions in ADCs, CAR-T, and autoimmune.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of the Liver (EASL) Congress, May 27-30, 2026, Barcelona. These presentations advance understanding of primary biliary cholangitis (PBC) and viral hepatitis. In PBC, Gilead will present randomized and long-term study data for Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union. Analyses fr.
Gilead Sciences, Inc. (GILD) Presents at Bank of America Global Healthcare Conference 2026 Transcript
GILD beats Q1 estimates as HIV and Trodelvy sales rise, but shares slip after the company cuts its 2026 EPS outlook.
Gilead Sciences, Inc. (GILD) Q1 2026 Earnings Call Transcript
Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Gilead Sciences (GILD) came out with quarterly earnings of $2.03 per share, beating the Zacks Consensus Estimate of $1.89 per share. This compares to earnings of $1.81 per share a year ago.
The biopharmaceutical company said it expects a 2026 adjusted loss of between $1.05 and 65 cents a share, compared with prior guidance of adjusted earnings between $8.45 and $8.85 a share.
Gilead Sciences on Thursday posted a higher-than-expected first-quarter profit and raised its outlook for 2026 sales, but said it now expects a loss for the year due to charges and financing costs related to recent acquisitions.
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter 2026. “Gilead teams have delivered another strong quarter with 8% year-over-year growth in our base business and 10% growth in HIV, supported by the successful launch of Yeztugo. We have raised our full year revenue guidance as a reflection of our performance," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. “Building on the strongest pipel.
LOS ANGELES--(BUSINESS WIRE)-- #AHFcares--Gilead's Earnings per Share Expected to Be Up 52% as Florida's and other States' AIDS Drug Programs Falters, says AHF.
Use of Gilead Sciences' Yeztugo, a twice-yearly injection to prevent HIV infection, has climbed since its June launch, but U.S. health providers say not all patients are interested in the new option and those who want to try it can face insurance coverage gaps.
Get a deeper insight into the potential performance of Gilead (GILD) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
This week, the California Supreme Court is set to hear a case that could have far-reaching consequences for medical science.
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Gilead Sciences gears up for Q1 earnings with HIV drugs driving growth, but cell therapy headwinds and rising costs could shape the outlook.
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities Health Care Conference on Tuesday, May 12 at 2:20 PM Pacific Time RBC Capital Markets Global Healthcare Conference on Tuesday, May 19 at 11:00 AM Eastern Time Bernstein Annual Strategic Decisions Conference on Thursday, May 28 at 11:00 AM Eastern Time Goldman Sachs Annual Global Healthcare Conference on Tuesday, Ju.
Gilead Sciences (GILD) closed at $130.84 in the latest trading session, marking a +1.55% move from the prior day.
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the First Trust NYSE Arca Biotechnology ETF (FBT), a passively managed exchange traded fund launched on June 19, 2006.
D.A. Davidson and CO. lifted its holdings in Gilead Sciences, Inc. (NASDAQ: GILD) by 8.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 66,923 shares of the biopharmaceutical company's stock after buying an additional 5,159 shares during the quarter. D.A. Davidson and
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) – an investigational, once-daily single-tablet combination regimen for the treatment of HIV in adults who are virologically suppressed. The FDA has granted priority review of the application and assigned a Prescription Drug User Fee Act (PDUFA) action date of Aug.
Amgen heads into Q1 earnings with growth from key drugs offset by pricing pressure, patent losses, and biosimilar competition.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (Nasdaq: ACLX). Under the terms of the transaction, Gilead acquired Arcellx for $115 per share in cash, plus one non‑transferable contingent value right (CVR) of $5 per share, representing a total implied equity value of approximately $7.8 billion at the time of closing. The acquisition builds on Kite, a Gilead Company, and.
The iShares Biotechnology ETF (IBB) was launched on 02/05/2001, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
It may not seem like it at first, but these dividends are safe.
LOS ANGELES--(BUSINESS WIRE)-- #AHFcares--AHF's Gilead Shareholder Resolution Seeks Transparency on Patent Exclusivities.
Brindle and Bay Financial Advisors LLC purchased a new stake in Gilead Sciences, Inc. (NASDAQ: GILD) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 6,042 shares of the biopharmaceutical company's stock, valued at approximately $742,000. Other institutional investors
